SCHEMBL516009

SCHEMBL516009

Cc1ccc(C)c(OC(C)O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.45
HTT P42858 1/20 0.45
TSHR P16473 3/20 0.43
CYP2C9 P11712 2/20 0.41
ACHE P22303 1/20 0.40
ADRB2 P07550 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
TDP1 Q9NUW8 4/20 0.38
TTR P02766 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2C8 P10632 1/20 0.38
CHRM1 P11229 1/20 0.38
ADRA1A P35348 1/20 0.38
PPARG P37231 1/20 0.38
HTR2B P41595 1/20 0.38
PPARA Q07869 1/20 0.38
SLCO1B3 Q9NPD5 1/20 0.38
CISD1 Q9NZ45 1/20 0.38
SLCO1B1 Q9Y6L6 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10359314 0.83 HTR2B (0.42) LMNATSHRACHESMN1; SMN2TDP1
SCHEMBL13059072 0.83 ACHE (0.43) LMNAHTTTSHRCYP2C9ACHE
SCHEMBL5286553 0.83 ACHE (0.43) LMNAHTTTSHRCYP2C9ACHE
SCHEMBL11691601 0.80 CASP1 (0.45) LMNAHTTTSHRSMN1; SMN2TDP1
SCHEMBL10359364 0.80 NPSR1 (0.48) LMNACYP2C9ACHESMN1; SMN2CYP1A2
SCHEMBL10358916 0.80 NPSR1 (0.46) LMNACYP2C9ACHESMN1; SMN2CYP1A2
SCHEMBL14394376 0.80 TSHR (0.36) LMNATSHRTDP1HTR2BGAA
SCHEMBL18231221 0.79 ACHE (0.40) LMNAHTTTSHRCYP2C9ACHE
SCHEMBL9774774 0.79 TSHR (0.44) LMNAHTTTSHRCYP2C9ACHE
SCHEMBL7277166 0.77 TDP1 (0.59) LMNAHTTTSHRCYP2C9SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111465589-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-01-05 CN disclosed
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same TEIJIN LIMITED (JP) 2022-05-24 US disclosed
EP-3747856-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME Teijin Limited (JP) 2020-12-09 EP disclosed
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME TEIJIN LIMITED (JP) 2020-11-12 US disclosed
CN-111465589-A Compound having fluorene skeleton and method for producing same 帝人株式会社 2020-07-28 CN disclosed
WO-2020085222-A1 CRYSTAL OF COMPOUND HAVING FLUORENE SKELETON AND METHOD FOR PRODUCING SAME 帝人株式会社 2020-04-30 WO disclosed
WO-2019151264-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME 帝人株式会社 2019-08-08 WO disclosed
CN-102388012-B Method for producing fluorene derivative TAOKA CHEMICAL Co.,Ltd. (JP) 2014-10-15 CN disclosed
US-8841491-B2 Method for producing fluorene derivative TAOKA CHEMICAL CO., LTD. (JP) 2014-09-23 US disclosed
EP-2420485-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE Taoka Chemical Co., Ltd. (JP) 2012-02-22 EP disclosed
US-20120029244-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE TAOKA CHEMICAL CO., LTD. (JP) 2012-02-02 US disclosed
EP-0391942-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1990-10-17 EP disclosed
US-4935540-A OXIDIZING ARYLOXYETHANOL IN PRESENCE OF PALLADIUM AND THALLIU M ON CARBON CATALYST, ACIDIFYING EASTMAN CHEMICAL COMPANY 1990-06-19 US disclosed
WO-1989003378-A1 PROCESS FOR THE PREPARATION OF ARYLOXYACETIC ACID EASTMAN KODAK COMPANY (US) 1989-04-20 WO disclosed
US-4804777-A OXIDATION OF ARYLOXYETHANOL USING PALLADIUM, SILVER, CARBON CATALYST EASTMAN KODAK COMPANY (US) 1989-02-14 US disclosed
EP-0011793-B1 PROCESS FOR PREPARING ARYLOXYACETIC ACIDS BAYER AG (DE) 1981-09-02 EP disclosed
US-4238625-A ACTIVATORS OF LEAD AND/OR BISMUTH AND/OR THEIR COMPOUNDS FOR OXIDATION WITH PLATINUM OR PALLADIUM CATALYST BAYER AKTIENGESELLSCHAFT (DE) 1980-12-09 US disclosed
EP-0011793-A1 Process for preparing aryloxyacetic acids BAYER AG (DE) 1980-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200354517-A1 COMPOUND HAVING FLUORENE SKELETON, AND METHOD FOR MANUFACTURING SAME RFT1, AFF1, RER1 LMNA 1995/4885HTT 2807/4885TSHR 2403/4885
US-20120029244-A1 METHOD FOR PRODUCING FLUORENE DERIVATIVE ADH1A, AFF2, AFF1 LMNA 1363/4885HTT 2816/4885TSHR 1365/4885
US-11339249-B2 Compound having fluorene skeleton, and method for manufacturing same RFT1, AFF1, RER1 LMNA 1995/4885HTT 2807/4885TSHR 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.